CYD Dengue Vaccine
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Withdrawn | EU (EMA) | Dengvaxia | — | 2025-10-21 | europa.eu ↗ |
| Approved | EU (EMA) | Dengvaxia | — | 2018-12-12 | europa.eu ↗ |
Trials 12 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05476757 Background | Aug 2022 → Jan 2023 | dengue disease | Mahidol University | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CYD Dengue Vaccine | “The aim of the study was to investigate the immunogenicity and safety of CYD dengue vaccine and Tetanus Toxoid (T), Reduced Diphtheria Toxoid (D) and Acellular Pertussis...” NCT02992418 ↗13“The purpose of this study is to investigate the potential for co-administration of the first dose of CYD Dengue vaccine with childhood vaccination.” NCT01064141 ↗ “CYD Dengue Vaccine” NCT01064141 ↗ “CYD Dengue Vaccine” NCT01411241 ↗ |
| Known as | CYD-TDV | “BACKGROUND: Incorporating dengue vaccination into existing childhood vaccination programs could increase vaccine coverage. This study assessed the safety and immunogenicity of...” PMID 34117198 ↗ Sep 20215“We assessed the immunogenicity and safety of a quadrivalent human papillomavirus (HPV) vaccine administered concomitantly or sequentially with a tetravalent dengue vaccine...” PMID 34250977 ↗ Aug 2021 “Three doses of the licensed tetravalent dengue vaccine CYD-TDV (Dengvaxia, Sanofi Pasteur, Lyon France) are immunogenic and effective against symptomatic dengue” PMID 33212067 ↗ Nov 2020 “The tetravalent dengue vaccine (CYD-TDV, Dengvaxia, Sanofi Pasteur) demonstrated efficacy in 2 previous phase III trials conducted in endemic countries.” PMID 30986790 ↗ May 2019 “The recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TDV) is recommended for dengue seropositive individuals” PMID 33992441 ↗ May 2021 “CYD-TDV, a live, attenuated, tetravalent dengue vaccine” PMID 33822015 ↗ Sep 2021 |
| Known as | Dengvaxia | “Three doses of the licensed tetravalent dengue vaccine CYD-TDV (Dengvaxia, Sanofi Pasteur, Lyon France) are immunogenic and effective against symptomatic dengue” PMID 33212067 ↗ Nov 20202“The tetravalent dengue vaccine (CYD-TDV, Dengvaxia, Sanofi Pasteur) demonstrated efficacy in 2 previous phase III trials conducted in endemic countries.” PMID 30986790 ↗ May 2019 “the participants will be vaccinated with Dengvaxia® until completion of 3 doses with 6-month interval between each dose.” NCT05476757 ↗ |
| Known as | Sanofi Pasteur's CYD Dengue Vaccine | “Sanofi Pasteur's CYD Dengue Vaccine” NCT00880893 ↗ |
| Modality | Vaccine | “CYD-TDV, a live, attenuated, tetravalent dengue vaccine” PMID 33822015 ↗ Sep 2021 |
| Route | Subcutaneous | “0.5 mL, Subcutaneous” NCT00842530 ↗ |